Compare Alliant Energy Corporation (LNT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Alliant Energy Corporation trades at $70.29 (market cap $17.78B), while State Street SPDR S&P Biotech ETF trades at $159. The key difference: Alliant Energy Corporation pays a 3.12% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Alliant Energy Corporation nearer its low. Which is the better fit depends on your goals.
| LNT | XBI | |
|---|---|---|
Market Cap | $17.78B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $78.03 | $164.28 |
52-Week Low | $63.62 | $86.92 |
Enterprise Value | $29.88B | — |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $70.01, up 2.64% today. The stock shows a bearish technical trend with support at $67-$68 and resistance at $69-$70. Fundamentally, the company reported strong Q2 2026 earnings of $0.65 per share, beating estimates, and maintains solid profitability with an 18.45% net income margin. Analyst consensus is a 'Buy' with a $77.67 price target, implying 11% upside. Recent news highlights institutional buying and dividend stability.
LNT offers a stable investment with consistent earnings growth and a reliable dividend, but faces risks from rising debt levels and regulatory pressures. The stock's current valuation at a P/E of 21.7 is reasonable for a utility, supporting a cautious bullish outlook amid technical weakness.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
